民和股份(002234.SZ):2月雞苗銷售收入同比降83.46%、環比降20.29%
格隆匯3月8日丨民和股份(002234.SZ)公佈2022年2月份雞苗銷售情況簡報,公司2022年2月銷售商品代雞苗1892.66萬隻,同比下降37.34%,環比下降20.62%;銷售收入2169.57萬元,同比下降83.46%,環比下降20.29%。
公司商品代雞苗銷量同比下降37.34%,主要原因是白羽肉雞行情較差,公司根據市場狀況主動降低了雞苗生產量所致;公司商品代雞苗銷售收入同比下降83.46%,主要原因是本期雞苗銷售均價較低,銷量較小,而去年同期市場需求旺盛,苗價較高同時公司加大產量所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.